2022
Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children
Halasa NB, Spieker AJ, Young CC, Olson SM, Newhams MM, Amarin JZ, Moffitt KL, Nakamura MM, Levy ER, Soma VL, Talj R, Weiss SL, Fitzgerald JC, Mack EH, Maddux AB, Schuster JE, Coates BM, Hall MW, Schwartz SP, Schwarz AJ, Kong M, Spinella PC, Loftis LL, McLaughlin GE, Hobbs CV, Rowan CM, Bembea MM, Nofziger RA, Babbitt CJ, Bowens C, Flori HR, Gertz SJ, Zinter MS, Giuliano JS, Hume JR, Cvijanovich NZ, Singh AR, Crandall HA, Thomas NJ, Cullimore ML, Patel MM, Randolph AG, Kong M, Gaspers M, Typpo K, Sanders R, Katherine I, Peter M, Schwarz A, Babbitt C, Helen H, Cvijanovich N, Zinter M, Maddux A, Osborne C, Sara S, Mourani P, Emily P, Van K, Carroll C, Giuliano J, McLaughlin G, Tarquinio K, Michelson K, Coates B, Rowan C, Wellnitz K, Bhoojhawon, Sullivan J, Montgomery V, Havlin K, Bradford T, Riggs B, Bembea M, Randolph A, Newhams M, Chen S, Young C, Moffitt K, Nakamura M, Carroll R, Yager P, Fernandes N, Flori H, Heidemann S, Hume J, Levy E, Hobbs C, Martin L, Malloch L, Inagaki K, Dhanrajani A, Schuster J, Kietzman A, Hill S, Spinella P, Cullimore M, McCulloh R, Clouser K, Gertz S, Kleinman L, Li S, Horwitz S, Ratner A, Dapul H, Soma V, Keenaghan M, Singh A, Harwayne-Gidansky I, Hymes S, Doymaz S, Schwartz S, Walker T, Hall M, Shein S, Lansell A, Nofziger R, Staat M, Fitzgerald J, Weiss S, Thomas N, Fink E, Carcillo J, Mack E, Smallcomb L, Halasa N, Stewart L, Romero Y, Hayek H, Loftis L, Munoz A, Bowens C, Maamari M, Crandall H, Smith L, McGuire J. Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children. Clinical Infectious Diseases 2022, 76: ciac477. PMID: 35717646, PMCID: PMC9384330, DOI: 10.1093/cid/ciac477.Peer-Reviewed Original ResearchMeSH KeywordsChildCOVID-19HospitalizationHumansInfluenza, HumanObesityRespiration, ArtificialRetrospective StudiesSARS-CoV-2ConceptsLife-threatening complicationsOdds of deathCoronavirus disease 2019Clinical characteristicsDisease 2019COVID-19US childrenLife supportHigher-acuity unitsInvasive mechanical ventilationShorter hospital stayNon-Hispanic blacksVasopressor supportHospital stayCritical illnessMembrane oxygenationPediatric patientsInfluenza infectionMechanical ventilationIntensive careClinical differencesUnderlying conditionDisease severityInfluenzaMixed-effects modelsA Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020
Schuster JE, Halasa NB, Nakamura M, Levy ER, Fitzgerald JC, Young CC, Newhams MM, Bourgeois F, Staat MA, Hobbs CV, Dapul H, Feldstein LR, Jackson AM, Mack EH, Walker TC, Maddux AB, Spinella PC, Loftis LL, Kong M, Rowan CM, Bembea MM, McLaughlin GE, Hall MW, Babbitt CJ, Maamari M, Zinter MS, Cvijanovich NZ, Michelson KN, Gertz SJ, Carroll CL, Thomas NJ, Giuliano JS, Singh AR, Hymes SR, Schwarz AJ, McGuire JK, Nofziger RA, Flori HR, Clouser KN, Wellnitz K, Cullimore ML, Hume JR, Patel M, Randolph AG, Investigators O. A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020. Journal Of The Pediatric Infectious Diseases Society 2022, 11: piab123-. PMID: 35022779, PMCID: PMC8807297, DOI: 10.1093/jpids/piab123.Peer-Reviewed Original ResearchMeSH KeywordsChildCOVID-19 Drug TreatmentCritical IllnessHospitalizationHospitals, PediatricHumansIntensive Care UnitsUnited StatesConceptsCOVID-19-directed therapiesAcute coronavirus disease 2019Life-threatening COVID-19COVID-19Acute COVID-19Underlying medical conditionsIntensive care unitHigh-acuity careCoronavirus disease 2019Half of childrenYears of ageCharacteristics of childrenRemdesivir useSystemic steroidsRespiratory supportClinical courseCare unitPediatric hospitalSpecific therapyPediatric dataIll childrenLaboratory valuesDisease 2019Medical conditionsUS hospitals
2021
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, Loftis LL, Tarquinio KM, Singh AR, Heidemann SM, Soma VL, Riggs BJ, Fitzgerald JC, Kong M, Doymaz S, Giuliano JS, Keenaghan MA, Hume JR, Hobbs CV, Schuster JE, Clouser KN, Hall MW, Smith LS, Horwitz SM, Schwartz SP, Irby K, Bradford TT, Maddux AB, Babbitt CJ, Rowan CM, McLaughlin GE, Yager PH, Maamari M, Mack EH, Carroll CL, Montgomery VL, Halasa NB, Cvijanovich NZ, Coates BM, Rose CE, Newburger JW, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. New England Journal Of Medicine 2021, 385: 23-34. PMID: 34133855, PMCID: PMC8220972, DOI: 10.1056/nejmoa2102605.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesCombined Modality TherapyCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleGlucocorticoidsHospitalizationHumansImmunoglobulins, IntravenousImmunomodulationInfantLogistic ModelsMalePropensity ScorePublic Health SurveillanceShockSystemic Inflammatory Response SyndromeTreatment OutcomeVentricular Dysfunction, LeftYoung AdultConceptsIntravenous immune globulinMultisystem inflammatory syndromeCardiovascular dysfunctionDay 2Immunomodulatory therapyInflammatory syndromePrimary outcomeInitial treatmentLower riskRisk of feverReal-world effectivenessYears of agePropensity-score matchingImmunomodulatory medicationsVasopressor useVentricular dysfunctionAdjunctive therapyComposite outcomeImmune globulinSecondary outcomesAdjunctive treatmentRecurrent feverInverse probability weightingDay 1GlucocorticoidsNeurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome
LaRovere KL, Riggs BJ, Poussaint TY, Young CC, Newhams MM, Maamari M, Walker TC, Singh AR, Dapul H, Hobbs CV, McLaughlin GE, Son MBF, Maddux AB, Clouser KN, Rowan CM, McGuire JK, Fitzgerald JC, Gertz SJ, Shein SL, Munoz AC, Thomas NJ, Irby K, Levy ER, Staat MA, Tenforde MW, Feldstein LR, Halasa NB, Giuliano JS, Hall MW, Kong M, Carroll CL, Schuster JE, Doymaz S, Loftis LL, Tarquinio KM, Babbitt CJ, Nofziger RA, Kleinman LC, Keenaghan MA, Cvijanovich NZ, Spinella PC, Hume JR, Wellnitz K, Mack EH, Michelson KN, Flori HR, Patel MM, Randolph AG, Last Name* F, Gaspers M, Typpo K, Sanders R, Schwarz A, Harvey H, Zinter M, Mourani P, Coates B, Bhoojhawon G, Havlin K, Montgomery V, Sullivan J, Bradford T, Bembea M, Lipton S, Graciano A, Chen S, Kucukak S, Newburger J, Carroll R, Fernandes N, Yager P, Marohn K, Heidemann S, Cullimore M, McCulloh R, Horwitz S, Li S, Walsh R, Ratner A, Soma V, Gillen J, Zackai S, Ackerman K, Cholette J, Harwayne-Gidansky I, Hymes S, Overby P, Schwartz S, Lansell A, Koncicki M, Carcillo J, Fink E, Kimura D, Bowens C, Crandall H, Smith L, Cengiz P. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurology 2021, 78: 536-547. PMID: 33666649, PMCID: PMC7936352, DOI: 10.1001/jamaneurol.2021.0504.Peer-Reviewed Original ResearchConceptsMultisystem inflammatory syndromeNeurologic involvementInflammatory syndromeLife-threatening conditionHospital dischargeTransient symptomsNeurologic conditionsPositive severe acute respiratory syndrome coronavirus 2 test resultCOVID-19Severe acute respiratory syndrome coronavirus 2Life-threatening neurologic conditionAcute respiratory syndrome coronavirus 2Long-term neurodevelopmental outcomesRespiratory syndrome coronavirus 2Fatal neurologic conditionFulminant cerebral edemaLife-threatening involvementNew neurologic deficitsAcute neurologic signsSyndrome coronavirus 2Coronavirus disease 2019Public health registriesFibrinogen equivalent unitsAdult patientsCerebral edema